ALX2004 starts phase 1, along with the sixth oncology-focused in vivo Car-T.
ApexOnco Front Page
Recent articles
If Pfizer hands back the estrogen receptor degrader, Arvinas will seek a new partner.
Raludotatug deruxtecan, ABBV-383 and zongertinib advance into phase 3, while other pivotal programmes are expanded.
Buoyed by the success of cadonilimab and ivonescimab the Chinese group takes two more bispecific MAbs into human trials.
The latest failure, in colorectal cancer, follows a recent disappointment in second-line liver.
As a key mid-stage readout approaches for the group’s neoantigen immunotherapy, Gritstone still has much to prove.
Crossover hits overall survival, pouring doubts on the group’s deal hopes.
After a rollercoaster existence Cellular Biomedicine Group has a new name, and new deals with AstraZeneca and J&J.